Brown Lisle Cummings Inc. Sells 1,337 Shares of Novo Nordisk A/S (NYSE:NVO)

Brown Lisle Cummings Inc. trimmed its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 2.7% during the fourth quarter, HoldingsChannel reports. The fund owned 48,858 shares of the company’s stock after selling 1,337 shares during the quarter. Novo Nordisk A/S comprises 1.3% of Brown Lisle Cummings Inc.’s holdings, making the stock its 18th largest position. Brown Lisle Cummings Inc.’s holdings in Novo Nordisk A/S were worth $4,203,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. AQR Capital Management LLC grew its stake in shares of Novo Nordisk A/S by 110.5% in the second quarter. AQR Capital Management LLC now owns 17,164 shares of the company’s stock worth $2,450,000 after purchasing an additional 9,012 shares during the last quarter. WealthBridge Capital Management LLC lifted its holdings in Novo Nordisk A/S by 8.4% during the 3rd quarter. WealthBridge Capital Management LLC now owns 6,780 shares of the company’s stock worth $807,000 after buying an additional 525 shares during the period. Azzad Asset Management Inc. ADV grew its position in shares of Novo Nordisk A/S by 55.9% in the 3rd quarter. Azzad Asset Management Inc. ADV now owns 41,107 shares of the company’s stock valued at $4,895,000 after buying an additional 14,731 shares during the last quarter. Parisi Gray Wealth Management increased its stake in shares of Novo Nordisk A/S by 19.6% in the third quarter. Parisi Gray Wealth Management now owns 3,990 shares of the company’s stock valued at $475,000 after buying an additional 653 shares during the period. Finally, Salvus Wealth Management LLC raised its position in shares of Novo Nordisk A/S by 6.9% during the third quarter. Salvus Wealth Management LLC now owns 3,064 shares of the company’s stock worth $365,000 after acquiring an additional 198 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $82.64 on Tuesday. The firm has a market capitalization of $370.85 billion, a P/E ratio of 26.74, a P/E/G ratio of 0.93 and a beta of 0.45. The firm’s 50-day moving average price is $93.56 and its 200-day moving average price is $112.87. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 1-year low of $78.17 and a 1-year high of $148.15.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on NVO shares. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Finally, BMO Capital Markets decreased their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Novo Nordisk A/S has an average rating of “Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.